Introduction

Dialysis access intervention encompasses the full spectrum of diagnostic and therapeutic endovascular procedures required to maintain functional hemodialysis vascular access. With over 500,000 patients receiving maintenance hemodialysis in the United States alone, the preservation of arteriovenous fistulas (AVF) and grafts (AVG) represents one of the most common and economically significant tasks in interventional radiology practice.

A well-functioning access is the lifeline for hemodialysis patients. When flow declines or thrombosis occurs, dialysis access intervention restores patency through fistulography, balloon angioplasty, stent graft placement, and mechanical or pharmacological thrombolysis. This article presents an evidence-based protocol for the assessment and endovascular management of failing dialysis access, designed for interventional radiologists, radiographers, and nephrology teams.

Vascular anatomy and access types

The native arteriovenous fistula is created by anastomosing a peripheral artery to an adjacent vein, most commonly the radial artery to the cephalic vein (Brescia-Cimino fistula) or the brachial artery to the cephalic or basilic vein. Fistulas require 6–12 weeks to mature before cannulation and offer superior long-term patency and lower infection rates compared to grafts.

Arteriovenous grafts are synthetic conduits (typically polytetrafluoroethylene, PTFE) bridging the artery and vein. They can be cannulated within 2–4 weeks but exhibit higher rates of infection, stenosis, and thrombosis. Common configurations include loop forearm, straight forearm, and upper arm configurations.

The venous outflow progresses from the cannulation segment through the peripheral veins to the central veins (subclavian, brachiocephalic, superior vena cava). Stenosis may occur at any level, but the juxta-anastomotic region and the venous anastomosis are the most frequent sites of pathology in fistulas and grafts, respectively.

Indications and surveillance

Indications for dialysis access intervention are broadly divided into physiological abnormalities detected by surveillance and clinical symptoms. Surveillance parameters include access flow <600 mL/min (grafts) or <400–500 mL/min (fistulas), elevated static or dynamic venous pressure, and decreased urea clearance (Kt/V).

Clinical indications include prolonged bleeding after needle removal, loss of thrill or bruit, extremity swelling suggesting venous outflow obstruction, and palpable pseudoaneurysm. Access thrombosis is an urgent indication requiring same-day intervention to prevent catheter dependence and preserve the access circuit.

Routine surveillance with monthly flow measurements and quarterly duplex ultrasound significantly improves primary assisted patency by detecting stenosis before thrombosis occurs. The National Kidney Foundation KDOQI guidelines recommend intervention when stenosis exceeds 50% and is accompanied by hemodynamic or clinical abnormalities.

Fistulogram technique

Access and initial imaging

The procedure begins with sterile preparation of the access circuit. Retrograde cannulation of the arterial limb or antegrade cannulation of the venous limb is performed with a 19G micropuncture needle or direct 6F sheath placement. A complete fistulogram evaluates the arterial anastomosis, the entire cannulation segment, the venous outflow, and the central veins.

Contrast is injected at 3–5 mL/s with digital subtraction acquisition at 3–6 fps. Roadmap fluoroscopy guides selective catheterization of stenotic segments. CO2 angiography is a useful alternative for patients with severe contrast allergy or marginal renal function, though it provides less detail in the arterial inflow.

Anatomical targeting

The most common sites of stenosis include the juxta-anastomotic segment (fistulas), the venous anastomosis (grafts), the peripheral draining veins, and the central veins (subclavian, brachiocephalic). Each site requires specific angiographic projections to profile the lesion and guide intervention. Biplane fluoroscopy is advantageous but not essential.

Angioplasty and stenting

Balloon angioplasty is the first-line treatment for dialysis access stenosis. High-pressure, non-compliant balloons are inflated to 10–20% oversizing relative to the reference vessel diameter. Inflation times of 30–60 seconds are standard, with prolonged inflation (2–3 minutes) for resistant lesions. The goal is residual stenosis <30% without flow-limiting dissection.

Cutting or scoring balloons (e.g., Peripheral Cutting Balloon) may improve outcomes in fibrotic or recurrent lesions. Drug-coated balloons have shown promise in peripheral arteries but evidence in dialysis access remains limited and their use is currently off-label in many jurisdictions.

Stent grafts (e.g., Viabahn, Fluency) are indicated for elastic recoil after angioplasty, rupture, or recurrent stenosis within 3 months. They should be used judiciously in the peripheral veins to preserve future access sites. Covered stents are particularly effective for treating graft-vein anastomotic stenosis and pseudoaneurysms.

Thrombectomy protocols

Thrombosed access requires removal of clot and treatment of the underlying stenosis. Mechanical thrombectomy using devices such as the Arrow-Trerotola or AngioJet fragments and aspirates thrombus. Pulse-spray pharmacological thrombolysis with tissue plasminogen activator (tPA) 2–4 mg diluted in saline can be used as an adjunct.

The lyse-and-wait technique involves instilling tPA into the thrombosed access and waiting 15–30 minutes before mechanical thrombectomy. This reduces clot burden and improves procedural efficiency. Post-thrombectomy angioplasty of the underlying stenosis is mandatory; without it, early recurrence is nearly universal.

After successful thrombectomy, heparin 1,000–3,000 units is administered to prevent immediate rethrombosis. The access may be cannulated for dialysis immediately if flow is adequate and no complications are evident.

Imaging parameters and contrast

Fluoroscopy for dialysis access intervention employs pulsed acquisition at 3–6 fps for fistulography and 2–3 fps for angioplasty monitoring. Digital subtraction angiography improves lesion conspicuity but may be limited by patient motion. Total contrast volume should be minimized; typical fistulograms require 30–60 mL of diluted non-ionic contrast.

CO2 angiography is an effective alternative for patients with contrast allergy or severe chronic kidney disease. It provides excellent visualization of venous outflow and central veins but is less effective for arterial inflow assessment. Ultrasound fusion imaging may guide cannulation in obese patients or those with deeply positioned accesses.

Radiation dose reduction and personnel safety

Dialysis access intervention—including fistulography, angioplasty, and thrombectomy—ranks among the highest-volume procedures in interventional radiology, with many operators performing multiple cases daily. The cumulative radiation burden for both patients and healthcare workers is therefore substantial. A single fistulogram with angioplasty may require 15–30 minutes of fluoroscopy time, and thrombectomy cases can exceed 45 minutes when combined with central venography.

Because dialysis patients undergo repeated interventions over months and years, their cumulative skin dose and lifetime stochastic risk are significant concerns. Every effort must be made to minimize dose per procedure. Ultrasound-guided cannulation of the access eliminates initial fluoroscopic localization. Pulsed fluoroscopy at the lowest clinically acceptable frame rate, tight collimation to the access circuit, and avoidance of magnification modes reduce dose without compromising procedural success.

Personnel protection strategies

The operator performing dialysis access intervention works in close proximity to the patient’s upper extremity and central venous system, positioning the hands and torso within the primary scatter field. Standard protection includes 0.5 mm lead-equivalent wraparound aprons, thyroid shields, and leaded eyewear. Ceiling-suspended shields are particularly effective during fistulography because the access site is superficial and the shield can be positioned close to the patient surface.

Table-side lead drapes placed under the patient’s arm and extending toward the operator attenuate scatter from the beam entrance site. Radiographers should be trained to step behind a mobile lead barrier during DSA acquisitions, as the scatter dose at 1 metre from the patient during a single DSA run can exceed the annual dose limit for extremities if repeated frequently without protection.

SATPro radiation protection solutions

The SATPro range delivers purpose-built radiation protection for high-volume vascular access suites. SATPro lightweight lead-composite aprons with ergonomic weight distribution reduce musculoskeletal strain for radiographers and nurses who wear protection for multiple consecutive cases. SATPro wraparound thyroid shields with 0.5 mm Pb equivalence provide 360-degree neck coverage during procedures requiring operator repositioning around the table.

For the dialysis access environment specifically, SATPro sterile disposable scatter-shield drapes are designed for draping over the patient’s shoulder and upper arm during fistulography, cutting scatter at the operator position by up to 65%. SATPro protective eyewear with anti-fog coatings ensures clear visualization during lengthy thrombectomy procedures while maintaining 0.75 mm Pb-equivalent lens protection. SATPro real-time dosimetry badges with wireless monitoring enable immediate feedback when dose rates exceed institutional action levels, empowering the team to adjust technique proactively.

Institutional dose governance

Effective radiation safety in the dialysis access lab extends beyond individual protective equipment. Institutions should establish dose reference levels (DRLs) for routine fistulography, angioplasty, and thrombectomy, with quarterly audits comparing individual operator and departmental performance against national benchmarks. Dose-sparing competitions, transparent reporting dashboards, and recognition programmes foster a culture where ALARA is operational rather than aspirational.

Equipment selection

Angioplasty balloons for dialysis access are typically 4–8 mm in diameter and 2–4 cm in length. High-pressure, non-compliant balloons (rated burst pressure >20 atm) are preferred for resistant venous stenosis. Stent grafts should be self-expanding nitinol devices with diameters 1–2 mm larger than the reference vessel.

Thrombectomy devices include the Arrow-Trerotola Percutaneous Thrombectomy Device, AngioJet rheolytic system, and manual aspiration thrombectomy catheters. Each has specific advantages: the Trerotola is effective for soft thrombus in grafts, while the AngioJet handles organized thrombus but carries a higher hemolysis risk.

Sheath selection depends on device requirements: 6F sheaths for standard angioplasty, 7–9F for stent grafts, and 6–8F for most thrombectomy devices. Hydrophilic wires (0.035-inch) and selective catheters (Kumpe, Cobra) facilitate traversal of tortuous or stenotic segments.

Complications and management

Complications of dialysis access intervention include vessel rupture (2–5%), distal embolization (2–3%), venous spasm, access site hematoma, and pseudoaneurysm formation. Vessel rupture is usually managed with prolonged balloon inflation or covered stent placement. Rarely, surgical repair is required for uncontained rupture.

Distal embolization of thrombus or atherosclerotic debris may occlude the arterial inflow or pulmonary circulation. Aspiration thrombectomy through a guiding catheter or surgical embolectomy may be necessary for limb-threatening events. Steal syndrome may worsen after aggressive angioplasty of the arterial inflow and requires careful hemodynamic assessment.

Access site complications are minimized by ultrasound-guided cannulation and meticulous hemostasis. Manual compression for 10–15 minutes or figure-of-eight suture closure is standard. Patients should avoid heavy lifting with the access extremity for 24–48 hours post-procedure.

Follow-up and surveillance

Post-intervention surveillance is critical for maintaining long-term patency. Duplex ultrasound is performed at 1 month post-angioplasty, then every 3 months thereafter. Clinical monitoring at each dialysis session includes flow assessment, venous pressure measurement, and physical examination for changes in thrill or bruit.

Primary patency after angioplasty is 40–60% at 6 months and 20–40% at 1 year. Assisted primary patency improves to 60–80% at 1 year with prompt re-intervention for recurrent stenosis. Secondary patency approaches 70–85% at 1 year with aggressive surveillance and maintenance programs.

Patients and dialysis staff should be educated to report prolonged bleeding, extremity swelling, or loss of access thrill immediately. Early detection of dysfunction allows elective intervention before thrombosis occurs, preserving access sites and reducing catheter dependence.

Conclusion

Dialysis access intervention is a high-volume, high-impact component of interventional radiology practice that directly affects patient morbidity, mortality, and quality of life. Success depends on systematic surveillance, prompt identification of hemodynamically significant stenosis, and mastery of angioplasty, stenting, and thrombectomy techniques.

Radiologists and nephrologists must collaborate closely to establish surveillance protocols, define intervention thresholds, and coordinate post-procedure care. For hospital administration, investing in dedicated access intervention programmes reduces central venous catheter utilization, lowers infection rates, and improves dialysis unit efficiency. Discover how SATMED Health supports comprehensive vascular access programme management.

References